Compare Abbott Laboratories (ABT) vs Google Inc (GOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Google Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Google Inc trades at $358 (market cap $4.46T). The key difference: Google Inc is far larger — about 26.7× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | GOOG | |
|---|---|---|
Market Cap | $166.94B | $4.46T |
Sector | Health | Technology |
52-Week High | $136.62 | $399.06 |
52-Week Low | $82.57 | $175.16 |
Enterprise Value | $193.69B | $4.42T |
Dividend Yield | 2.63% | 0.24% |
Volume | — | 1,511,127 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GOOG trades at $363.62, up 2.09% today, reflecting strong momentum after consecutive earnings beats. The stock shows a bullish technical trend with support at $358 and resistance at $369. Revenue grew to $402.84B in 2025, with net income reaching $132.17B, driven by robust profitability margins. Recent news highlights Google's AI advancements and a dividend payment, reinforcing investor confidence.
Outlook remains positive with a consensus price target of $457.50, indicating 26% upside. Risks include competitive pressures in AI and regulatory scrutiny. Analyst sentiment is overwhelmingly bullish (86.84% buy ratings), supported by strong cash flow growth and strategic investments in fusion technology and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
